|Day Low/High||233.19 / 235.00|
|52 Wk Low/High||166.30 / 235.80|
Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.
According to the charts, the drugmaker should break out to new highs.
These stocks are priced for total imperfection. That's just what you want.
Markets are watching what Fed Chair Powell will signal for future rate cuts during this afternoon's FOMC rate decision.
If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
Before I give my recommendation I want to visit with the charts and indicators.
RMPIA is up 20.9% in the first nine months of 2019.
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.
Let's check out the charts to get a sense of where prices could be headed.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Gains in Amgen, CVS, and others helped offset declines in other stocks, as the RMPIA rose over the last two months to 0.6%, handily beating all the major domestic stock market averages.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.